ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices.

ViiV Healthcare, announced positive initial findings from the CUSTOMIZE trial (Cabotegravir plus Rilpivirine in the US To Optimize and Measure Implementation and Experience) which aims to identify successful methods of implementing the investigational once-monthly, long-acting regimen of cabotegravir and rilpivirine for the treatment of HIV-1 into clinical practice. Since the CUSTOMIZE study began, a team from ViiV Healthcare worked with physicians, nurses, clinic administrators, and patients across a range of medical practices, including federally qualified health centers, academic medical centers and private physician offices. Its goal was to find the most practical and efficient ways to implement a monthly injectable treatment regimen which, if approved, could create a paradigm shift in HIV treatment, including increasing the frequency of clinic visits from once or twice per year to every month. Four months into the study, the majority of clinical staff participants continued to perceive the implementation of the once-monthly injectable regimen as highly acceptable, feasible and appropriate for people living with HIV, and had a substantial decrease in what they thought would be barriers to implementation of the injectable regimen. These initial findings were presented today at the virtual 23rd International AIDS Conference (AIDS 2020).